Xenera-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in women with HR+ / HER2- metastatic breast cancer and non-visceral disease
Latest Information Update: 10 Sep 2020
At a glance
- Drugs Xentuzumab (Primary) ; Everolimus; Exemestane
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms XENERA-1
- Sponsors Boehringer Ingelheim
- 16 Jul 2020 Planned primary completion date changed from 14 Oct 2021 to 15 Dec 2021.
- 05 May 2020 Status changed from suspended to recruiting.
- 04 May 2020 Planned primary completion date changed from 25 Aug 2021 to 14 Oct 2021.